Background: Schisandra chinensis Turcz. (Baill.) is a perennial deciduous woody vine
plant, which is beneficial to all systems of the body.
Objective: The goals of the present study were to compare the pharmacokinetics of schisandrol B in
rats after the oral administration of schisandrol B monomer (10 mg/kg) and S. chinensis extract (equivalent
to 10 mg/kg schisandrol B) and to explore interactions among the components in S. chinensis
Methods: Twelve Sprague-Dawley rats of SPF grade were randomly divided into the monomer and
S.chinensis extract groups. Plasma samples were extracted with methyl tert-butyl ether, and chromatographic
separation was performed on an Agilent ZORBAX Eclipse XDB-C18 (4.6 × 150 mm, 5 μm)
column with the mobile phase consisting of methanol (containing 0.1% formic acid)-water (containing
0.1% formic acid and 5 mmol ammonium acetate). This analysis was achieved by multiple reaction
monitoring modes in an electrospray interface.
Results: The seven lignans had a good linear relationship within the determination range (r>0.9950);
the intra- and inter-day precision was < 12.08% and accuracy was 88.64%-111.61%. The pharmacokinetic
parameters (T1/2, Tmax, MRT0-∞, CL, AUC0-t, and AUC0-∞) of schisandrol B showed significant
differences between the two groups (P <0.05).
Conclusion: The validated method has been successfully applied to the pharmacokinetics of schisandrin,
schisandrol B, schisandrin A, schisandrin B, schisandrin C, schisanhenol, and schisantherin A.
The pharmacokinetic differences indicate that other components in the extract may increase the absorption
of schisandrol B, decrease the rate of elimination, and improve the bioavailability of schisandrol B.